Overview

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-06-26
Target enrollment:
Participant gender:
Summary
To characterize safety associated with the use of Kyprolis under the locally approved label.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Lenalidomide